Objectives: 

1.  To understand the challenges in performing genome-wide studies to identify genetic markers associated with chemotherapeutic toxicities.

2.  To understand both modifiable risk factors associated with cisplatin-induced ototoxicity and peripheral neuropathy.

3.  To understand the lack of diversity in pharmacogenomic studies and its impact on health outcomes.